{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:08:55Z","timestamp":1789524535238,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.purol.2012.07.006","type":"journal-article","created":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T01:30:37Z","timestamp":1345771837000},"page":"954-962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiohormonoth\u00e9rapie dans le cancer de la prostate \u00e0 haut risque\u00a0: quels r\u00e9sultats sur une population Antillaise\u00a0?"],"prefix":"10.1016","volume":"22","author":[{"given":"A.D.","family":"Foahom Kamwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Agoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"S\u00e9n\u00e9chal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Bentaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fofana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Manip-M\u2019Ebobisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Blanchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2012.07.006_bib0005","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC cancer based no\u00a010. Lyon: IARC, 2010. Available from: http:\/\/globocan.iarc.fr. [Accessed 24\/01\/2012]."},{"key":"10.1016\/j.purol.2012.07.006_bib0010","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.juro.2006.09.024","article-title":"Epidemiology and pathophysiology of prostate cancer in African-American men","volume":"177","author":"Powell","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2012.07.006_bib0015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ijc.23500","article-title":"Investigating Black-White differences in prostate cancer prognosis: a systematic review and meta-analysis","volume":"123","author":"Evans","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.purol.2012.07.006_bib0020","first-page":"165","article-title":"Prostate cancer in Guadeloupe (French West Indies): incidence, mortality and clinicopathological features","volume":"96","author":"Brureau","year":"2009","journal-title":"Bull Cancer"},{"key":"10.1016\/j.purol.2012.07.006_bib0025","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2009.27.2153","article-title":"Chlordecone exposure and risk of prostate cancer","volume":"28","author":"Multigner","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.purol.2012.07.006_bib0030","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0360-3016(00)01423-1","article-title":"The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer","volume":"49","author":"D\u2019Amico","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl.\u00a04","key":"10.1016\/j.purol.2012.07.006_bib0035","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/S1166-7087(10)70042-7","article-title":"Recommendations onco-urology 2010: prostate cancer","volume":"20","author":"Salomon","year":"2010","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2012.07.006_bib0040","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.purol.2012.07.006_bib0045","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","article-title":"An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone\/radiation interactions","volume":"69","author":"Lawton","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.purol.2012.07.006_bib0050","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2007.11.066","article-title":"Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes","volume":"71","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.purol.2012.07.006_bib0055","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ijrobp.2008.12.082","article-title":"Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma","volume":"75","author":"Aizer","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.purol.2012.07.006_bib0060","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ijrobp.2010.07.1975","article-title":"Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?","volume":"81","author":"Zapatero","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.purol.2012.07.006_bib0065","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-4295(99)00436-7","article-title":"Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease","volume":"55","author":"Powell","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.purol.2012.07.006_bib0070","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2001.19.1.54","article-title":"Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience","volume":"19","author":"Connell","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.purol.2012.07.006_bib0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1557988309353934","article-title":"Do African-American men have lower survival from prostate cancer compared with White men? A meta-analysis","volume":"4","author":"Sridhar","year":"2010","journal-title":"Am J Mens Health"},{"key":"10.1016\/j.purol.2012.07.006_bib0080","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.urology.2009.02.058","article-title":"Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer","volume":"74","author":"Schwartz","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.purol.2012.07.006_bib0085","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1186\/1471-2407-10-675","article-title":"Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials","volume":"10","author":"Cuppone","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.purol.2012.07.006_bib0090","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ijrobp.2008.05.009","article-title":"Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors","volume":"73","author":"Nguyen","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.purol.2012.07.006_bib0095","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.eururo.2010.07.034","article-title":"Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature","volume":"58","author":"Lughezzani","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2012.07.006_bib0100","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1002\/cncr.24346","article-title":"Biomolecular markers of outcome prediction in prostate cancer","volume":"115","author":"Lopergolo","year":"2009","journal-title":"Cancer"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670871200200X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670871200200X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:22:01Z","timestamp":1761114121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S116670871200200X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":20,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S116670871200200X"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2012.07.006","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiohormonoth\u00e9rapie dans le cancer de la prostate \u00e0 haut risque\u00a0: quels r\u00e9sultats sur une population Antillaise\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2012.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}